The Role of Permanent Brachytherapy in the Treatment of Localized Prostate Carcinoma
Authors:
R. Soumarová; L. Homola; H. Perková; M. Bulik
Authors place of work:
Oddělení radioterapie a onkologie, Komplexní onkologické centrum Nový Jičín
Published in the journal:
Klin Onkol 2010; 23(3): 141-145
Category:
Reviews
Summary
The popularity of permanent brachytherapy is now growing dramatically. The development of several new technologies has led to an improvement in dose distribution and results and can also return the patients to normal daily activities. The role of permanent brachytherapy in the treatment of localized prostate carcinoma is described in the present article. Indications and contraindications and a comparison of the results with other modalities of treatment are discussed. Emphasis is also placed on the morbidity of the treatment and the quality of life, which plays a very important role in the process of making a decision as to which therapy should be applied. Permanent brachytherapy is most often used separately, but in certain cases may be combined with external radiotherapy and hormonal treatment.
Key words:
prostate cancer – implant radiotherapy – morbidity
Zdroje
1. Aus G, Abbou CC, Bolla M et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2005; 48(4): 546– 551.
2. Potters L, Morgenstern C, Calugaru E et al. 12‑year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173(5): 1562– 1566.
3. Zelefsky MJ, Kuban DA, Levy LB et al. Multi‑institutional analysis of long‑term outcome for stages T1– T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007; 67(2): 327– 333.
4. Battermann JJ, Boon TA, Moerland MA. Results of permanent prostate brachytherapy: 13 years of experience at a single institution. Radiother Oncol 2004; 71(1): 23– 28.
5. Grimm PD, Blasko JC, Sylvester JE et al. 10- Year biochemic (prostate‑ specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51(1): 31– 40.
6. Ash D, Flynn A, Battermann J et al. ESTRA/ EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/ EAU/ EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57(3): 315– 321.
7. Nag S, Beyer D, Friedland J et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44(4): 789– 799.
8. Henry AM, Al‑ Qaisieh B, Gould K et al. Outcomes following iodine‑ 125 monotherapy for localized prostate cancer: the results of leeds 10‑year single‑center brachytherapy experience. Int J Radiat Oncol Biol Phys 2010; 76(1): 50– 56.
9. Cosset JM, Flam T, Thiounn N et al. Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/ Cochin Hospital/ Necker Hospital group on 809 patients. Int J Radiat Oncol Biol Phys 2008; 71(4): 1042– 1048.
10. Young HH. Treatment of carcinoma of the prostate. In: Young HH, Davis DM (eds). Young’s practice of urology: Based on a study of 12,500 cases. 1st ed. Philadelphia: WB Saunders 1926; 644– 671.
11. Flocks R, Kerr H, Elkins H et al. The treatment of carcinoma of the prostate by interstitial radiation with radioactive gold: A Follow up report. J Urol 1959; 71: 628– 633.
12. Whitmore W jr, Hilaris B, Grabstald H. Retropubic implantation of iodine‑ 125 in the treatment of prostate cancer. J Urol 1972; 108(6): 918– 920.
13. Zelefsky MJ, Whitmore WF Jr. Long‑term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol 1997; 158(1): 23– 29.
14. Holm HH, Juul N, Pedersen JF et al. Transperineal I‑ 125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130: 283– 286.
15. Norderhaug I, Dahl O, Høisaeter PA at al. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. Eur Urol 2003; 44(1): 40– 46. Review.
16. D‘Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280(11): 969– 974.
17. Wong WW, Vora SA, Schild SE et al. Radiation dose escalation for localized prostate cancer: intensity‑ modulated radiotherapy versus permanent transperineal brachytherapy. Cancer 2009; 115(23): 5596– 5606.
18. Eade TN, Horwitz EM, Ruth K et al. A comparison of acute and chronic toxicity for men with low‑ risk prostate cancer treated with intensity‑ modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 2008; 71(2): 338– 345.
19. Jabbari S, Weinberg VK, Shinohara K et al. Equivalent biochemical control and improved prostate‑ specific antigen nadir after permanent prostate seed implant brachytherapy versus high‑dose three‑ dimensional conformal radiotherapy and high‑dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 2010; 76(1): 36– 42.
20. Martinez AA, Demanes J, Vargas C et al. High‑Dose‑Rate Prostate Brachytherapy: An Excellent Accelerated‑ Hypofractionated Treatment for Favorable Prostate Cancer. Am J Clin Oncol 2009 Nov 30. [Epub ahead of print]
21. Shapiro EY, Rais‑ Bahrami S, Morgenstern C et al. Long‑term outcomes in younger men following permanent prostate brachytherapy. J Urol 2009; 181(4): 1665– 1671; discussion 1671.
22. Merrick GS, Wallner KE, Galbreath RW et al. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ‑ confined prostate cancer. Am J Clin Oncol 2008; 31(6): 539– 544.
23. Lee WR, DeSilvio M, Lawton C et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate‑ risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P‑ 0019. Int J Radiat Oncol Biol Phys 2006; 64(3): 804– 809.
24. Zelefsky MJ, Nedelka MA, Arican ZL et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity‑ modulated radiation therapy. Brachytherapy 2008; 7(1): 1– 6.
25. Dattoli M, Wallner K, True L et al. Long‑term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high‑risk features. Cancer 2007; 110(3): 551– 555.
26. Critz FA, Levinson AK, Williams WH et al. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external‑ beam radiation. Cancer J Sci Am 1998; 4(6): 359– 363.
27. Roeloffzen EM, Lips IM, van Gellekom MP et al. Health‑ Related Quality of Life up to Six Years After (125)I Brachytherapy for Early‑ Stage Prostate Cancer. Int J Radiat Oncol Biol Phys 2010; 76(4): 1054– 1060.
28. Ash D, Bottomley D, Al Qaisieh B et al. A prospective analysis of long‑term quality of life after permanent I‑ 125 brachytherapy for localised prostate cancer. Radiother Oncol 2007; 84(2): 135– 139.
29. Bottomley D, Ash D, Al‑ Qaisieh B et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 2007; 82(1): 46– 49.
30. Eapen L, Kayser C, Deshaies Y et al. Correlating the degree of needle trauma during prostate brachytherapy and the development of acute urinary toxicity. Int J Radiat Oncol Biol Phys 2004; 59: 1392– 1394.
31. Lee WR, McQuellon RP, Harris‑ Henderson K et al. A preliminary analysis of health‑related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46(1): 77– 81.
32. Kleinberg L, Wallner K, Roy J et al. Treatment‑related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 1994; 28(4): 985– 990.
33. Zelefsky MJ, Hollister T, Raben A et al. Five‑year biochemical outcome and toxicity with transperineal CT‑ planned permanent I‑ 125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47(5): 1261– 1266.
34. Merrick GS, Butler WM, Wallner KE et al. Long‑term rectal function after permanent prostate brachytherapy. Cancer J 2007; 13(1): 95– 104.
35. Robinson JW, Moritz S, Fung T. Meta‑analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54(4): 1063– 1068.
36. Burnett AL, Aus G, Canby- Hagino ED et al. American Urological Association Prostate Cancer Guideline Update Panel. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007; 178(2): 597– 601.
37. Feigenberg SJ, Lee WR, Desilvio ML et al. Health‑related quality of life in men receiving prostate brachytherapy on RTOG 98– 05. Int J Radiat Oncol Biol Phys 2005; 62(4): 956– 964.
38. Henderson A, Laing RW, Langley SE. Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review. Eur Urol 2004; 45(2): 134– 141. Review.
39. Baxter NN, Tepper JE, Durham SB et al. Increased risk of rectal cancer after prostate radiation: a population‑based study. Gastroenterology 2005; 128(4): 819– 824.
40. Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008; 180(5): 2005– 2009; discussion 2009– 2010.
41. Kucway R, Vicini F, Huang R et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002; 167(6): 2443– 2447.
42. Mitchell DM, Swindell R, Elliott T et al. Analysis of prostate‑ specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Radiother Oncol 2008; 88(1): 102– 107.
43. Thompson A, Keyes M, Pickles T et al. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 2010 Feb 2. [Epub ahead of print].
44. Patel C, Elshaikh MA, Angermeier K et al. PSA bounce predicts early success in patients with permanent iodine‑ 125 prostate implant. Urology 2004; 63(1): 110– 113.
45. Aaronson DS, Yamasaki I, Gottschalk A et al. Salvage permanent perineal radioactive‑ seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009; 104(5): 600– 604.
46. Burri RJ, Stone NN, Unger P et al. Long‑Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2010 Feb 4. [Epub ahead of print].
47. Wei Z, Wan G, Gardi L et al. Robot‑ assisted 3D‑ TRUS guided prostate brachytherapy: system integration and validation. Med Phys 2004; 31(3): 539– 548.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2010 Číslo 3
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Staging of Non‑ Hodgkin’s Lymphoma – Recommendations of the Czech Lymphoma Study Group
- The Current Role of Haematopoietic Stem Cell Transplantation in the Treatment of Lymphomas – Review
- Impact of Oncological Treatment on Human Reproduction
- What is the Clinically Appropriate Approach to a Terminally Ill Oncological Patient?